Abbott Elliot, Young Robert Steve, Hale Caroline, Mitchell Kimberly, Falzone Nadia, Vallis Katherine A, Kennedy Andrew
Oxford Institute for Radiation Oncology, Department of Oncology, Oxford University, Oxford, United Kingdom.
Radiology Alliance, Centennial Medical Center, Nashville, Tennessee.
Adv Radiat Oncol. 2020 Nov 24;6(2):100617. doi: 10.1016/j.adro.2020.11.002. eCollection 2021 Mar-Apr.
Selective internal radiation therapy (SIRT) is administered to treat tumors of the liver and is generally well tolerated. Although widely adopted for its therapeutic benefits, SIRT is rarely combined with external beam radiation therapy (EBRT) owing to the complexity of the dosimetry resulting from the combination of treatments with distinct radiobiological effects. The purpose of this study was to establish a dosimetric framework for combining SIRT and EBRT using clinical experience derived from representative patients with hepatocellular carcinoma (HCC) who received both therapies.
Treatments from 10 patients with HCC given EBRT either before or after SIRT were analyzed. The dosimetry framework used here considered differences in the radiobiological effects and fractionation schemes of SIRT versus EBRT, making use of the concepts of biological effective dose (BED) and equivalent dose (EQD). Absorbed dose from SIRT was calculated, converted to BED, and summed with BED from EBRT dose plans. Two of these patients were used in a virtual planning exercise to investigate the feasibility of combining stereotactic body radiation therapy and SIRT.
The combination of EBRT and SIRT in 10 patients with HCC showed no major toxicity. No Child-Pugh scores went above 8 and albumin-bilirubin scores from only 1 patient worsened to grade 3 (> -1.39) from treatment through 3-months follow-up. A framework with radiobiological modeling was developed to manage the combined treatments in terms of their sum BED. The exploratory SIRT plus SABR inverse dose plans for 2 patients, incorporating radiobiologically informed Y SIRT dosimetry, achieved dose distributions comparable to SBRT alone.
Treatment with both EBRT and SIRT can be given safely to patients with HCC. The BED and EQD concepts should be used in combined dosimetry to account for the differing radiobiological effects of EBRT and SIRT. Inverse dose planning of EBRT after SIRT could provide improved dose distributions and flexibility to the clinical workflow. Further research into combination therapy is needed through prospective trials.
选择性体内放射治疗(SIRT)用于治疗肝脏肿瘤,一般耐受性良好。尽管SIRT因其治疗益处而被广泛采用,但由于两种具有不同放射生物学效应的治疗方法联合使用时剂量测定的复杂性,SIRT很少与外照射放疗(EBRT)联合使用。本研究的目的是利用来自接受过这两种治疗的代表性肝细胞癌(HCC)患者的临床经验,建立一个将SIRT和EBRT联合使用的剂量测定框架。
分析了10例在SIRT之前或之后接受EBRT的HCC患者的治疗情况。这里使用的剂量测定框架考虑了SIRT与EBRT在放射生物学效应和分割方案上的差异,利用了生物等效剂量(BED)和等效剂量(EQD)的概念。计算SIRT的吸收剂量,将其转换为BED,并与EBRT剂量计划的BED相加。其中两名患者被用于虚拟计划练习,以研究立体定向体部放射治疗与SIRT联合使用的可行性。
10例HCC患者联合使用EBRT和SIRT未显示出重大毒性。没有Child-Pugh评分超过8分,并且从治疗到3个月随访期间,只有1例患者的白蛋白-胆红素评分从治疗前恶化至3级(> -1.39)。开发了一个具有放射生物学模型的框架,以根据总BED来管理联合治疗。针对2例患者的探索性SIRT加立体定向消融放疗(SABR)逆向剂量计划,纳入了放射生物学指导的Y SIRT剂量测定,实现了与单独SBRT相当的剂量分布。
EBRT和SIRT联合治疗对HCC患者是安全的。在联合剂量测定中应使用BED和EQD概念,以考虑EBRT和SIRT不同的放射生物学效应。SIRT后进行EBRT的逆向剂量计划可为临床工作流程提供更好的剂量分布和灵活性。需要通过前瞻性试验对联合治疗进行进一步研究。